CD8A and neoplasm: Moreover, acetate, as a regulator for immune checkpoint ligand PVR/CD155 driven by PI3K/AKT signaling, can enhance functional responses of CD8+ T cells in TIME and promote the production of IFN-γ, which is expected to become a related drug to promote tumor immunity.